IMA AUTOMATION Joins BIOTOOL-CHF Project to personalize pharmacological approaches in congestive heart failure

THE PROJECT

BIOmarker-Based Diagnostic TOOLkit to Personalize Pharmacological Approaches in Congestive Heart Failure

IMA AUTOMATION is proud to announce its participation in the BIOTOOL-CHF Project (BIOmarker-Based Diagnostic TOOLkit to Personalize Pharmacological Approaches in Congestive Heart Failure). This ambitious initiative aims to provide an innovative approach to managing heart failure with reduced ejection fraction, one of the most frequent, costly, and deadly conditions in Europe. BIOTOOL-CHF will deliver technological solutions to personalize current treatment options and reduce the disease burden. IMA AUTOMATION will specifically be responsible for drafting a detailed business plan that also indicates the regulatory steps necessary to bring this prototype to the commercial market.

Project Overview

• Duration: 4 years (2023 - 2026)
• Partners: 23 organizations across Europe

Key Goals and Technological Developments

The main objective of BIOTOOL-CHF is to enhance the efficiency of diuretic therapy for patients with heart failure with reduced ejection fraction through personalization. This will be achieved using a decision-making tool that integrates diagnostic and prognostic information from a selected array of biomarkers with each patient's clinical and demographic characteristics.

BIOTOOL-CHF research activities will identify a selected pool of biomarkers validated for predicting fluid overload, which will be implemented in a companion diagnostic prototype. This tool, combined with a fluid retention score and a prognostic score, integrated with specific patient characteristics, will form the basis for developing the BIOTOOL-CHF Decision-Making Tool. This tool will help healthcare providers manage fluid balance effectively.

Funded Project by the European Union